Neoplasm Malignant

Oncology
16
Pipeline Programs
4
Companies
14
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
13
2
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
13 programs
11
1
1
SAR125844Phase 21 trial
SAR245408Phase 1/21 trial
Aflibercept AVE0005Phase 11 trial
SAR245408Phase 11 trial
SAR245408Phase 11 trial
+8 more programs
Active Trials
NCT01930552Completed20Est. Dec 2014
NCT01943838Completed18Est. Feb 2015
NCT01392924Completed10Est. Nov 2014
+9 more trials
Sutro Biopharma
Sutro BiopharmaSOUTH SAN FRANCISCO, CA
1 program
1
STRO-002Phase 1/21 trial
Active Trials
NCT06238687Recruiting132Est. Dec 2027
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
PSB205Phase 1
Sound Biologics
Sound BiologicsWA - Bothell
1 program
1
PSB205Phase 11 trial
Active Trials
NCT03986606Unknown64Est. Jul 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
SanofiSAR125844
Sutro BiopharmaSTRO-002
SanofiSAR245408
SanofiSAR442257
Sound BiologicsPSB205
SanofiSAR408701
SanofiSAR428926
SanofiSAR408701
SanofiSAR245408
SanofiAflibercept AVE0005
SanofiSAR260301
SanofiSAR405838
SanofiSAR245409
SanofiSAR245408

Clinical Trials (14)

Total enrollment: 876 patients across 14 trials

NCT02435121SanofiSAR125844

A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification

Start: Nov 2015Est. completion: Jan 20161 patients
Phase 2Completed
NCT06238687Sutro BiopharmaSTRO-002

A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors

Start: Nov 2023Est. completion: Dec 2027132 patients
Phase 1/2Recruiting
NCT01587040SanofiSAR245408

Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

Start: Jul 2012Est. completion: May 201861 patients
Phase 1/2Completed
NCT04401020SanofiSAR442257

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Start: Jul 2020Est. completion: Mar 202647 patients
Phase 1Active Not Recruiting
NCT03986606Sound BiologicsPSB205

A Study of PSB205 in Subjects With Advanced Solid Tumors

Start: Jul 2019Est. completion: Jul 202164 patients
Phase 1Unknown
NCT03324113SanofiSAR408701

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

Start: Oct 2017Est. completion: Dec 202234 patients
Phase 1Completed
NCT02575781SanofiSAR428926

A Study of SAR428926 in Patients With Advanced Solid Tumors

Start: Oct 2015Est. completion: Jun 201834 patients
Phase 1Completed
NCT02187848SanofiSAR408701

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

Start: Jul 2014Est. completion: Nov 2024254 patients
Phase 1Terminated
NCT01943838SanofiSAR245408

A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma

Start: Oct 2013Est. completion: Feb 201518 patients
Phase 1Completed
NCT01930552SanofiAflibercept AVE0005

A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies

Start: Sep 2013Est. completion: Dec 201420 patients
Phase 1Completed
NCT01673737SanofiSAR260301

A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

Start: Aug 2012Est. completion: Feb 201575 patients
Phase 1Completed
NCT01636479SanofiSAR405838

Phase 1 Safety Testing of SAR405838

Start: Jul 2012Est. completion: Mar 201877 patients
Phase 1Completed
NCT01596270SanofiSAR245409

A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma

Start: Jun 2012Est. completion: Oct 201449 patients
Phase 1Completed
NCT01392924SanofiSAR245408

Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors

Start: Aug 2011Est. completion: Nov 201410 patients
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1m ago

Office Administrator

SystImmune
1m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
12m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
15m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
15m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 876 patients
4 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)